Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06986174 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
A Phase 2 study of Lymphoplasmacytic Lymphoma and Waldenström Macroglobulinemia, sponsored by Shayna Sarosiek, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06986174 is a Phase 2 study of Lymphoplasmacytic Lymphoma and Waldenström Macroglobulinemia that is actively recruiting participants, run by Shayna Sarosiek, MD. The registered enrollment target is 30 participants, below the 107-participant average among 18 other Lymphoplasmacytic Lymphoma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06986174, a Phase 2 study of Lymphoplasmacytic Lymphoma and Waldenström Macroglobulinemia, is actively recruiting participants, sponsored by Shayna Sarosiek, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to examine the safety and effectiveness of pacritinib as a possible treatment for participants with Waldenström macroglobulinemia (WM). The name of the study drug involved in this study is: -Pacritinib (a type of kinase inhibitor)
Conditions Studied
Interventions
- DRUG Pacritinib
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-11-21 |
| Est. Completion | 2032-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06986174
The ClinicalTrials.gov registry entry for NCT06986174 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 107-participant average among 18 other Lymphoplasmacytic Lymphoma trials with a reported enrollment target (72% lower). The listed sponsor is Shayna Sarosiek, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Lymphoplasmacytic Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Pacritinib is the first listed.
NCT06986174 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06986174 about?
NCT06986174 is a clinical study titled "A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia". This study is being done to examine the safety and effectiveness of pacritinib as a possible treatment for participants with Waldenström macroglobulinemia (WM). The name of the study drug involved in this study is: -Pacritinib (a type of kinase inhibitor)
What is the current status of trial NCT06986174?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-11-21. Estimated completion is 2032-10-01.
What conditions does trial NCT06986174 study?
This clinical trial studies the following conditions: Lymphoplasmacytic Lymphoma, Waldenström Macroglobulinemia, B-Cell Lymphoproliferative Disorder, Indolent Lymphoma.
What interventions are being tested in trial NCT06986174?
The interventions under investigation include: Pacritinib (DRUG).
Who is sponsoring clinical trial NCT06986174?
This trial is sponsored by Shayna Sarosiek, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06986174 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoplasmacytic Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RECRUITING · Phase 2
-
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RECRUITING · Phase 2
-
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Lymphoplasmacytic Lymphoma
All registered trials for this condition
Waldenström Macroglobulinemia
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.